CHOP-21 for the treatment of post-transplant lymphoproliferative disorders following solid organ transplantation

Haematologica

Volumn 92, Issue 2, 2007, Pages 273-274

  Choquet, Sylvain ^a   Trappe, Ralf Ulrich ^a,b   Leblond, Veronique ^a   Jäger, Ulrich ^c   Davi, Frederic ^a   Oertel, Stephan ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Chemotherapy; CHOP; Immunosuppression; Post transplant lymphoproliferative disorder; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; IMMUNOSUPPRESSIVE AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; MALE; MONOTHERAPY; ORGAN TRANSPLANTATION; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT RESPONSE; COHORT ANALYSIS; DISEASE FREE SURVIVAL; LETTER; METHODOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PREDNISONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINCRISTINE;

EID: 33947492166     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10595     Document Type: Article

References (10)

1. Garrett TJ, Chadburn A, Barr ML, Drusin RE, Chen JM, Schulman LL, et al. Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy. Cancer 1993;72:2782-5.
2. Mamzer-Bruneel MF, Lome C, Morelon E, Levy V, Bourquelot P, Jacobs F, et al. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: a report of 16 cases observed in a single center. J Clin Oncol 2000;18:3622-32.
3. Norin S, Kimby E, Ericzon BG, Christensson B, Sander B, Soderdahl G, et al. Posttransplant lymphoma: a single-center experience of 500 liver transplantations. Med Oncol 2004;21:273-84.
4. Buell JF, Gross TG, Hanaway MJ, Trofe J, Muthiak C, First MR, et al. Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc 2005; 37: 956-7.
5. Elstrom RL, Andreadis C, Aqui NA, Ahya VN, Bloom RD, Brozena SC, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006;6:569-76.
6. Fohrer C, Caillard S, Koumarianou A, Ellero B, Woehl-Jaegle ML, Meyer C, et al. Long-term survival in posttransplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen. Br J Haematol 2006;134:602-12.
7. Taylor AL, Bowles KM, Callaghan CJ, Wimperis JZ, Grant JW, Marcus RE, et al. Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation. Transplantation 2006;82:375-81.
8. Oertel SH, Verschuuren E, Reinke P, Zeidler K, Papp-Vary M, Babel N, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005;5:2901-6.
9. Choquet S, Leblond V, Herbrecht R, Socie G, Stoppa AM, Vandenberghe P, et al. Efficacy and safety of rituximab in B-cell post-transplant lymphoproliferative disorders: results of a prospective multicentre phase II study. Blood 2006;107:3053-7.
10. Trappe R, Oertel SH, Choquet S, LeBlond V, Papp-Vary M, Riess H. Sequential treatment with the anti-CD 20 antibody rituximab and CHOP+GCSF chemotherapy in patients with post-transplant lymphoproliferative disorder (PTLD): first results of a multicenter phase II study. Blood 2005;106:932.